Efficacy and safety of mioinositol as monotherapy or combination therapy in women with polycystic ovary syndrome:
a systematic review
Abstract
Polycystic ovary syndrome is a complex endocrinopathy characterized by ovulatory dysfunction, hyperandrogenism, and insulin resistance. Due to the limitations and adverse effects of conventional therapies, mioinositol has emerged as a physiological insulin sensitizer with a favorable safety profile.
Objective: To systematically evaluate the efficacy and safety of mioinositol as monotherapy or in combination therapy in women with PCOS, assessing its effects on reproductive, hormonal, and metabolic outcomes, as well as clinical tolerability.
Methods: A systematic review was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO. Clinical trials and observational studies published between 2020 and 2025 were identified in PubMed, VHL, SciELO, ScienceDirect, and Cochrane Library. Methodological quality was assessed using RoB 2.0 and ROBINS-I tools.
Results: Thirty studies were included; the administration of myo-inositol, particularly in combination with synergistic components, demonstrated a substantial reduction in the HOMA-IR index and a substantial decrease in total testosterone levels, accompanied by menstrual cycle regularization and an improvement in the ovulation rate, with a minimal incidence of mild adverse effects.
Conclusion: Mioinositol is an effective and safe therapeutic option for PCOS management. Its ability to modulate endocrine and metabolic pathways, combined with its favorable safety profile, supports its role as a first-line or adjunctive therapy.
Downloads
References
Salari N, Nankali A, Ghanbari A, Jafarpour S, Ghasemi H, Dokaneheifard S, et al. Global prevalence of polycystic ovary syndrome in women worldwide: a comprehensive systematic review and meta-analysis. Arch Gynecol Obstet [Internet]. 2024 [consultado 2026 Sep 1];310(3):1303–14. Disponible en: https://doi.org/10.1007/s00404-024-07607-x
Sirmans S, Pate K. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol [Internet]. 2013 [consultado 2026 Oct 5];1. Disponible en: https://doi.org/10.2147/CLEP.S37559
Deswal R, Narwal V, Dang A, Pundir C. The prevalence of polycystic ovary syndrome: a brief systematic review. J Hum Reprod Sci [Internet]. 2020 [consultado 2026 Nov 10];13(4):261. Disponible en: https://doi.org/10.4103/jhrs.JHRS_95_18
Liu J, Wu Q, Hao Y, Jiao M, Wang X, Jiang S, et al. Measuring the global disease burden of polycystic ovary syndrome in 194 countries: Global Burden of Disease Study 2017. Hum Reprod [Internet]. 2021 [consultado 2026 Dec 3];36(4):1108–19. Disponible en: https://doi.org/10.1093/humrep/deaa371
Espinosa ME, Sánchez R, Otzen T, Bautista-Valarezo E, Aguiar S, Corrales Gutierrez I, et al. Phenotypic characterization of patients with polycystic ovary syndrome in a population from the Ecuadorian Andes: a cross-sectional study [Internet]. 2023 [consultado 2027 Jan 15]. Disponible en: https://doi.org/10.20944/preprints202312.2225.v1
Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod
[Internet]. 2018 [consultado 2027 Feb 20];33(9):1602–18. Disponible en: https://doi.org/10.1093/humrep/dey256
Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab [Internet]. 2013 [consultado 2026 Sep 12];98(12):4565–92. Disponible en: https://doi.org/10.1210/jc.2013-2350
Devalaraja-Narashimha K, Padanilam BJ. PARP-1 inhibits glycolysis in ischemic kidneys. J Am Soc Nephrol [Internet]. 2009 [consultado 2026 Oct 18];20(1):95–103. Disponible en: https://doi.org/10.1681/ASN.2008030325
Martínez-Loría HJ, Vargas-Zúñiga LF, González-Vargas JA, Cordero-Robles KM, Urrea-Mayorga MJ. Papel del mioinositol en la regulación hormonal femenina y el síndrome de ovario poliquístico. Rev Tecnol Marcha [Internet]. 2024 [consultado 2026 Nov 7]. Disponible en: https://doi.org/10.18845/tm.v37i4.6939
Lete I, Martínez A, Lasaga I, Centurión E, Vesga A. Update on the combination of mioinositol/d-chiro-inositol for the treatment of polycystic ovary syndrome. Gynecol Endocrinol [Internet]. 2024 [consultado 2026 Dec
;40(1). Disponible en: https://doi.org/10.1080/09513590.2023.2301554
Unfer V, Facchinetti F, Orrù B, Giordani B, Nestler J. Mioinositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocr Connect [Internet]. 2017 [consultado 2027 Jan 8];6(8):647–58. Disponible en: https://doi.org/10.1530/EC-17-0243
Tabrizi R, Ostadmohammadi V, Lankarani KB, Peymani P, Akbari M, Kolahdooz F, et al. The effects of inositol supplementation on lipid profiles among patients with metabolic diseases: a systematic review and meta analysis of randomized controlled trials. Lipids Health Dis [Internet]. 2018 [consultado 2027 Feb 2];17(1):123. Disponible en: https://doi.org/10.1186/s12944-018-0779-4
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. Declaración PRISMA 2020: una guía actualizada para la publicación de revisiones sistemáticas. Rev Esp Cardiol [Internet]. 2021 [consultado 2026 Sep 14];74(9):790–9. Disponible en: https://doi.org/10.1016/j.recesp.2021.06.016
Pkhaladze L, Russo M, Unfer V, Nordio M, Basciani S, Khomasuridze A. Treatment of lean PCOS teenagers: a follow-up comparison between mioinositol and oral contraceptives. Eur Rev Med Pharmacol Sci [Internet].
[consultado 2026 Oct 9];25(23):7476–85. Disponible en: https://doi.org/10.26355/eurrev_202112_27447
Ahmed S, Khan SP, Izhar S, Rashid S, Waraich RS, Sohail FA. Comparison of various therapeutic approaches to manage infertility in polycystic ovarian syndrome. J Coll Physicians Surg Pak [Internet]. 2024 [consultado 2026 Nov 6];34(6):654–8. Disponible en: https://doi.org/10.29271/jcpsp.2024.06.654
Nordio M, Basciani S, Camajani E. The 40:1 mioinositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. Eur Rev Med Pharmacol Sci [Internet]. 2019 [consultado
Dec 12];23(12):5512–21. Disponible en: https://doi.org/10.26355/eurrev_201906_18223
Nas K, Tűű L. A comparative study between mioinositol and metformin in the treatment of insulin-resistant women. Eur Rev Med Pharmacol Sci [Internet]. 2017 [consultado 2027 Jan 4];21(2 Suppl):77–82. Disponible en:
https://pubmed.ncbi.nlm.nih.gov/28724173/
Rolland AL, Peigné M, Plouvier P, Dumont A, Catteau-Jonard S, Dewailly D. Could mioinositol soft gel capsules outperform clomiphene in inducing ovulation? Results of a pilot study. Eur Rev Med Pharmacol Sci [Internet]. 2017 [consultado 2027 Feb 1];21(2 Suppl):10–4. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28724178/
Hernandez Marin I, Picconi O, Laganà AS, Costabile L, Unfer V. A multicenter clinical study with mioinositol and alpha-lactalbumin in Mexican and Italian PCOS patients. Eur Rev Med Pharmacol Sci [Internet]. 2021 [consultado 2026 Sep 21];25(8):3316–24. Disponible en: https://doi.org/10.26355/eurrev_202104_25743
Montanino Oliva M, Buonomo G, Calcagno M, Unfer V. Effects of mioinositol plus alpha-lactalbumin in mioinositol-resistant PCOS women. J Ovarian Res [Internet]. 2018 [consultado 2026 Oct 30];11(1):38. Disponible
en: https://doi.org/10.1186/s13048-018-0411-2
Troisi J, Cinque C, Giugliano L, Symes S, Richards S, Adair D, et al. Metabolomic change due to combined treatment with mioinositol, D-chiro inositol and glucomannan in polycystic ovarian syndrome patients: a pilot
study. J Ovarian Res [Internet]. 2019 [consultado 2026 Nov 25];12(1):25. Disponible en: https://doi.org/10.1186/s13048-019-0500-x
Aguilar-Mora ME, Torres BM, Chávez DV, Méndez GL, López OP. Efecto y tolerancia gastrointestinal de mioinositol vs metformina en el control metabólico y hormonal de pacientes con síndrome de ovario poliquístico.
Ginecol Obstet Mex [Internet]. 2020 [consultado 2026 Dec 18];89(3). Disponible en: https://ginecologiayobstetricia.org.mx/
Io CR, Saucedo-De-La-Llata E, Mr MS, Romeu-Sarrió A. Myoinositol plus D-chiro-inositol: preliminary results as first line management in PCOS. Ginecol Obstet Mex [Internet]. 2017 [consultado 2027 Jan 10]. Disponible en: https://ginecologiayobstetricia.org.mx/
Isabella R, Raffone E. CONCERN: Does ovary need D-chiro-inositol? J Ovarian Res [Internet]. 2012 [consultado 2027 Feb 14];5(1):14. Disponible en: https://doi.org/10.1186/1757-2215-5-14
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. Declaración PRISMA 2020: una guía actualizada para la publicación de revisiones sistemáticas. Rev Esp Cardiol [Internet]. 2021 [consultado 2026 Sep 14];74(9):790–9. Disponible en: https://doi.org/10.1016/j.recesp.2021.06.016
Pkhaladze L, Russo M, Unfer V, Nordio M, Basciani S, Khomasuridze A. Treatment of lean PCOS teenagers: a follow-up comparison between mioinositol and oral contraceptives. Eur Rev Med Pharmacol Sci [Internet].
[consultado 2026 Oct 9];25(23):7476–85. Disponible en: https://doi.org/10.26355/eurrev_202112_27447
Ahmed S, Khan SP, Izhar S, Rashid S, Waraich RS, Sohail FA. Comparison of various therapeutic approaches to manage infertility in polycystic ovarian syndrome. J Coll Physicians Surg Pak [Internet]. 2024 [consultado 2026 Nov 6];34(6):654–8. Disponible en: https://doi.org/10.29271/jcpsp.2024.06.654
Nordio M, Basciani S, Camajani E. The 40:1 mioinositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. Eur Rev Med Pharmacol Sci [Internet]. 2019 [consultado
Dec 12];23(12):5512–21. Disponible en: https://doi.org/10.26355/eurrev_201906_18223
Nas K, Tűű L. A comparative study between mioinositol and metformin in the treatment of insulin-resistant women. Eur Rev Med Pharmacol Sci [Internet]. 2017 [consultado 2027 Jan 4];21(2 Suppl):77–82. Disponible en:
https://pubmed.ncbi.nlm.nih.gov/28724173/
Rolland AL, Peigné M, Plouvier P, Dumont A, Catteau-Jonard S, Dewailly D. Could mioinositol soft gel capsules outperform clomiphene in inducing ovulation? Results of a pilot study. Eur Rev Med Pharmacol Sci [Internet]. 2017 [consultado 2027 Feb 1];21(2 Suppl):10–4. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28724178/
Hernandez Marin I, Picconi O, Laganà AS, Costabile L, Unfer V. A multicenter clinical study with mioinositol and alpha-lactalbumin in Mexican and Italian PCOS patients. Eur Rev Med Pharmacol Sci [Internet]. 2021 [consultado 2026 Sep 21];25(8):3316–24. Disponible en: https://doi.org/10.26355/eurrev_202104_25743
Montanino Oliva M, Buonomo G, Calcagno M, Unfer V. Effects of mioinositol plus alpha-lactalbumin in mioinositol-resistant PCOS women. J Ovarian Res [Internet]. 2018 [consultado 2026 Oct 30];11(1):38. Disponible en: https://doi.org/10.1186/s13048-018-0411-2
Troisi J, Cinque C, Giugliano L, Symes S, Richards S, Adair D, et al. Metabolomic change due to combined treatment with mioinositol, D-chiro inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study. J Ovarian Res [Internet]. 2019 [consultado 2026 Nov 25];12(1):25. Disponible en: https://doi.org/10.1186/s13048-019-0500-x
Aguilar-Mora ME, Torres BM, Chávez DV, Méndez GL, López OP. Efecto y tolerancia gastrointestinal de mioinositol vs metformina en el control metabólico y hormonal de pacientes con síndrome de ovario poliquístico. Ginecol Obstet Mex [Internet]. 2020 [consultado 2026 Dec 18];89(3). Disponible en: https://ginecologiayobstetricia.org.mx/
Io CR, Saucedo-De-La-Llata E, Mr MS, Romeu-Sarrió A. Myoinositol plus D-chiro-inositol: preliminary results as first line management in PCOS. Ginecol Obstet Mex [Internet]. 2017 [consultado 2027 Jan 10]. Disponible en: https://ginecologiayobstetricia.org.mx/
Isabella R, Raffone E. CONCERN: Does ovary need D-chiro-inositol? J Ovarian Res [Internet]. 2012 [consultado 2027 Feb 14];5(1):14. Disponible en: https://doi.org/10.1186/1757-2215-5-14
Andavar M, Kamaraj R, Mahalingam Vijayakumar T, Murugesan A. Effectiveness of dual combination therapy of acarbose plus metformin and acarbose plus mioinositol in ameliorating the metabolic and endocrinologic
complications of polycystic ovary syndrome: a randomized controlled trial. Eur J Obstet Gynecol Reprod Biol [Internet]. 2024 [consultado 2026 Sep 16];300:611. Disponible en: https://doi.org/10.1016/j.ejogrb.2024.07.001
Greff D, Juhász AE, Váncsa S, Váradi A, Sipos Z, Szinte J, et al. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol [Internet]. 2023 [consultado 2026 Oct 19];21(1):10. Disponible en: https://doi.org/10.1186/s12958-023-01055-z
Zhang J, Zhang H, Zhou W, Jiang M, Lin X. Effect of mioinositol supplementation in mixed ovarian response IVF cohort: a systematic review and meta-analysis. Front Endocrinol (Lausanne) [Internet]. 2025 [consultado 2026 Nov 27];16:1520362. Disponible en: https://doi.org/10.3389/fendo.2025.1520362
Azizi Kutenaei M, Hosseini Teshnizi S, Ghaemmaghami P, Eini F, Roozbeh N. The effects of mioinositol vs. metformin on the ovarian function in the polycystic ovary syndrome: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci [Internet]. 2021 [consultado 2026 Dec 8];25(7):3105–15. Disponible en:
https://doi.org/10.26355/eurrev_202104_25565
Zhang JQ, Xing C, He B. Short period-administration of mioinositol and metformin on hormonal and glycolipid profiles in patients with polycystic ovary syndrome: a systematic review and updated meta-analysis of randomized controlled trials. Eur Rev Med Pharmacol Sci [Internet]. 2022 [consultado 2027 Jan 9];26(6):1792–802. Disponible en: https://doi.org/10.26355/eurrev_202203_28322
Showell MG, Mackenzie-Proctor R, Jordan V, Hodgson R, Farquhar C. Inositol for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev [Internet]. 2018 [consultado 2027 Feb 6];12(12). Disponible en: https://doi.org/10.1002/14651858.CD012378.pub2
Copyright (c) 2026 Byron Ruben Herrera Artos, Esmeralda Maricela Estrada Zamora
This work is licensed under a Creative Commons Attribution 4.0 International License.
The authors retain their copyright and assign to the journal the right of first publication of their work, which will be simultaneously subject to the Creative Commons Attribution 4.0 International License. that allows sharing the work as long as the initial publication in this magazine is indicated.
